Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your endometrial cancer has come back (recurrent) and can be seen on scans (measurable) or has “detectable” disease like fluid or small/untargetable spots
- Your tumor must be deficient in mismatch repair (dMMR), confirmed by lab tests (IHC and/or MSI testing)
- You must be 18 or older and well enough to do daily activities (ECOG 0–2)
- You need blood test levels adequate for treatment (including platelets, neutrophils) and your kidneys/liver should be within allowed limits
- You must have recovered from any recent surgery, chemotherapy, or radiation (usually at least 4 weeks; hormonal therapy at least 3 weeks)
- If you’ve had immune therapy before, it must fit the study rules (allowed only in certain situations), and you should not have had severe immune side effects that stopped immunotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding Avastin (bevacizumab) to the standard combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (Keytruda) for advanced or recurrent endometrial cancer with a specific genetic makeup (pMMR and TP53 mutation). The goal is to see if adding Avastin helps shrink tumors or slow their growth.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial studies a new drug called cadonilimab combined with chemotherapy for women with endometrial cancer that has come back or spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.
This study tests whether immunotherapy, a treatment that helps your immune system attack cancer cells, is effective against advanced or recurrent endometrial cancer. It aims to see how well the treatment works based on specific genetic markers in your tumor.
This Phase 2 study tests two immunotherapy medicines (nivolumab and ipilimumab) in people with metastatic colorectal cancer that has not responded to anti-PD1 treatment. It focuses on tumors with mismatch repair problems (dMMR) and/or high microsatellite instability (MSI).
Hear when a new Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.